Summary of 2008 NamedExecutive Officer Cash Compensation

The Compensation Committee of our Board of Directors has approved 2008 base salaries for our named executive officers as set forth below.

The Compensation Committee has also approved a process for the determination of 2008 cash bonuses for our named executive officers, pursuant to which bonuses will be determined in the discretion of the Compensation Committee based on the achievement of certain corporate and individual goals in 2008.  The corporate goals include objectives relating to the development of drug candidates and the achievement of specified financial targets.  The achievement of these goals will be evaluated by the Compensation Committee in making determinations regarding bonuses for 2008 performance.  The Compensation Committee has established a bonus target, expressed as a percentage of base salary, for each of our named executive officers, assuming that corporate and individual goals are fully achieved.  The bonus target percentage for each of our named executive officers is set forth below.

Name and Position		2008 Base Salary				2008 Bonus Target
Arthur T. Sands, M.D., Ph.D. President and Chief Executive Officer		$	560,000				50	%
Julia P. Gregory Executive Vice President and Chief Financial Officer		$	350,000				35	%
Alan J. Main, Ph.D. Executive Vice President of Pharmaceutical Research		$	340,000				35	%
Jeffrey L. Wade, J.D. Executive Vice President and General Counsel		$	340,000				35	%
Brian P. Zambrowicz, Ph.D. Executive Vice President and Chief Scientific Officer		$	365,000				40	%